Survodutide
Metabolic
A dual GLP-1/glucagon receptor agonist being developed for obesity, NASH/MASH, and type 2 diabetes.
Community
0
Tracking
0
Doses Logged
0.6mg/week
Common Dose
—
Adverse Rate
All dosages:0.6mg/week2.4mg/week4.8mg/week
Reported Adverse Effects
No adverse effects reported yet
Community Consensus
No consensus claims yet — be the first to contribute
Literature
No studies linked yet — know of one? Share it in the discussion
Discussion
No discussion yet — be the first to share your experience